Replies to post #168 on Equity Field Notes from temporal sources

[DanWebzster]

CORI 's Alzheimer strategy looks like the best way to profit from this malady in the stock market.

Its Aracept weekly patch is a cholinergic treatment with GI benefits over the oral medication. It is being evaluated by the FDA under the 505B2 pathway for bioequivalence.

NDA submission for the Aracept patch will likely take place 1-2/19

CORI is also taking eh bioequivalece pathway for their Mementine patch. Mementine is the second most subscribed Alzheimer medication.

CORI will not commercialize these products. They are looking for partners.

Cash runway could extend to the presently anticipated PDUFA date for the Aracept patch.

Their primary source of income right now is the manufacturing and technology of Crest White Strips for Proctor & Gamble. CORI is in the middle of a project to meet increasing demand for this product by expanding production capacity.

CORI burned $18mn in the most recent Q. Revs increased ~42% YOY.

CORI is also involved in helping its partner address a CRL for Twirla